- Home
- AMLX
as 10-27-2025 9:35am EST
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 749.9M | IPO Year: | 2022 |
| Target Price: | $16.86 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.60 - $16.96 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | -77.06% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Amylyx Pharmaceuticals Inc. (AMLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Sep 30 '25 | Sell | $14.67 | 29,933 | $429,468.84 | 3,325,347 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Sep 30 '25 | Sell | $14.58 | 8,828 | $128,668.98 | 148,141 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Sep 30 '25 | Sell | $14.69 | 29,975 | $430,952.12 | 3,325,301 | |
| Bedrosian Camille L | AMLX | Chief Medical Officer | Sep 30 '25 | Sell | $14.58 | 12,039 | $175,517.78 | 182,336 | |
| FRATES JAMES M | AMLX | Chief Financial Officer | Sep 30 '25 | Sell | $14.65 | 10,558 | $154,650.42 | 280,430 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Aug 13 '25 | Sell | $8.34 | 15,000 | $125,046.00 | 148,141 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Aug 12 '25 | Sell | $8.07 | 15,000 | $121,102.50 | 148,141 |
Latest Amylyx Pharmaceuticals Inc. News
AMLX Breaking Stock News: Dive into AMLX Ticker-Specific Updates for Smart Investing
Motley Fool
4 months ago
Why Shares in Amylyx Pharmaceuticals Soared This Week
Insider Monkey
4 months ago
Amylyx Pharmaceuticals Gains FDA Fast Track for ALS Drug AMX0114
MT Newswires
4 months ago
Guggenheim Initiates Amylyx Pharmaceuticals at Buy With $17 Price Target
MT Newswires
5 months ago
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday
MT Newswires
5 months ago
Amylyx Pharmaceuticals' Potential ALS Treatment Gets FDA Fast Track Designation
Business Wire
5 months ago
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
MT Newswires
5 months ago
TD Cowen Initiates Coverage on Amylyx Pharmaceuticals With Buy Rating
Business Wire
5 months ago
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences
Compare AMLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMLX Amylyx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.